GLP-1glp-1sglt-2masldhepatology

Hepatology issues erratum on GLP-1 and SGLT-2 combination MASLD study

The correction applies to work by Mao, Fan, Yuen and colleagues on liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes.

By Maren Holt · Senior Reporter, GLP-1

Sep 23 20:00 ETSource: Hepatology (Baltimore, Md.)

The wire

01Hepatology published an erratum dated September 24 for a study of GLP-1 receptor agonist plus SGLT-2 inhibitor therapy and major adverse liver and cardiovascular outcomes.
02Clinicians citing the original analysis in MASLD and type 2 diabetes should check the corrected version before relying on its estimates.
03The notice does not specify what was changed; readers should consult the erratum text alongside the original paper.

From the source

Erratum: GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes
Hepatology (Baltimore, Md.) · 2026 Sep 24 · Mao X, Fan H, Yuen MF et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42782120/